OCP/DARS new clinical studies IDIQ 5 year contract with M ceiling

The Food and Drug Administration has issued a five-year IDIQ contract with a $50 million ceiling to support new clinical studies under the OCP/DARS program. This procurement is designed to provide flexible, long-term acquisition support for innovative clinical research initiatives, with the NAICS code 541714 indicating the scope involves research and development in the physical, engineering, and life sciences. The contract will be managed by the FDA’s Center for Drug Evaluation and Research, with the primary point of contact for program inquiries being the Cder Acquisition Liaison via cderacquisitions@fda.hhs.gov. The contracting officer position is currently listed as to be determined, and the place of performance details have not been specified. All work under this contract is anticipated to support FDA’s mission in evaluating the safety and efficacy of medical products through the development and oversight of new clinical trials. The forecast was posted on May 25, 2026, and interested parties can access additional information through the OSDBU opportunity portal.